NKX6-3 in B-Cell Progenitor Differentiation and Leukemia

Area of Science:

• Hematology
• Molecular Biology
• Oncology

Background:

• Early B-cell development involves sequential differentiation stages regulated transcriptionally.
• B-cell precursor acute lymphoblastic leukemia (BCP-ALL) originates from these stages and is driven by aberrant transcription factors (TFs).
• Understanding physiological TFs is crucial for deciphering normal and aberrant regulatory networks in B-cell development and BCP-ALL.

Purpose of the Study:

• To investigate the role of NKX6-3, a homeodomain TF, in normal B-cell progenitors and TCF3::PBX1-positive BCP-ALL.
• To establish the gene regulatory network associated with NKX6-3 in BCP-ALL.
• To identify novel diagnostic markers and therapeutic targets within these regulatory networks.

Main Methods:

• siRNA-mediated knockdown and forced expression experiments in BCP-ALL model cell lines.
• Gene regulatory network construction involving NKX6-3, IRX1, MEIS1, and SPIB.
• Comparative expression profiling of public BCP-ALL patient data and RNA-sequencing (RNA-seq) analysis.

Main Results:

• NKX6-3 forms a gene regulatory network with IRX1, MEIS1, and SPIB, and is activated by TCF3::PBX1 in BCP-ALL.
• CD109, a TGFb-pathway inhibitor, is a downregulated target of NKX6-3, with reciprocal activation between TGFb-signalling and NKX6-3.
• MPP7 is upregulated by both NKX6-3 and TCF3::PBX1, implicating the HIPPO-pathway in B-cell progenitors and TCF3::PBX1-positive BCP-ALL.

Conclusions:

• Novel players and regulatory connections in TF-networks of B-cell progenitors and BCP-ALL have been identified.
• NKX6-3 plays a significant role in the aberrant TF-networks of TCF3::PBX1-positive BCP-ALL.
• The identified regulatory network components, including NKX6-3, CD109, and MPP7, represent potential diagnostic markers or therapeutic targets.